Coherus BioSciences Interest Expense 2011-2026 | CHRS

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Coherus BioSciences

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
40.5 M	32.5 M	23 M	21.2 M	17.6 M	9.68 M	9.55 M	7.98 M	33 K	3.9 M	5.29 M	1.51 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
40.5 M	33 K	14.4 M

Quarterly Interest Expense Coherus BioSciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
2.32 M	2.28 M	2.15 M	-	2.83 M	4.06 M	3.12 M	-	10.3 M	9.94 M	9.71 M	-	7.54 M	6.58 M	8.97 M	-	5.77 M	5.75 M	5.65 M	-	5.66 M	5.41 M	4.43 M	-	4.47 M	4.43 M	4.22 M	-	2.42 M	2.42 M	2.41 M	-	2.39 M	2.38 M	2.38 M	-	2.42 M	2.35 M	837 K	-	33 K	-139 K	-4.09 M	-	1 K	1.16 M	2.74 M	-	1.99 M	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
10.3 M	-4.09 M	3.71 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
Adagene ADAG	1.11 M	$ 1.65	7.91 %	$ 92.9 M	China
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.59	1.99 %	$ 8.64 B	Australia
Arrowhead Pharmaceuticals ARWR	5.26 M	$ 66.05	2.3 %	$ 8.83 B	USA
Autolus Therapeutics plc AUTL	9.29 M	$ 1.52	-16.3 %	$ 388 M	Britain
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Biogen BIIB	250 M	$ 184.48	-1.67 %	$ 26.9 B	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 4.25	1.67 %	$ 9.25 B	Israel
BeiGene, Ltd. BGNE	-12.6 M	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
Bristol-Myers Squibb Company BMY	-893 M	$ 55.71	-0.28 %	$ 113 B	USA
Ascendis Pharma A/S ASND	65.5 M	$ 207.49	2.22 %	$ 5 B	Danmark
Codiak BioSciences CDAK	2.7 M	-	-55.98 %	$ 2.15 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Cerevel Therapeutics Holdings CERE	10.6 M	-	-	$ 7.29 B	USA
Zai Lab Limited ZLAB	2.25 M	$ 18.37	-0.97 %	$ 18.2 B	China
Catalyst Biosciences CBIO	1.04 M	$ 10.84	0.46 %	$ 714 M	USA
Caladrius Biosciences CLBS	-257 K	-	-16.75 %	$ 25.8 M	USA
Celldex Therapeutics CLDX	927 K	$ 25.59	-6.54 %	$ 1.65 M	USA
Cellectis S.A. CLLS	371 K	$ 4.22	-4.2 %	$ 116 M	France
Chimerix CMRX	11 M	-	-	$ 756 M	USA
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
Catalyst Pharmaceuticals CPRX	21.1 M	$ 23.18	2.02 %	$ 2.75 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Crinetics Pharmaceuticals CRNX	8 K	$ 55.11	3.49 %	$ 4.45 B	USA
CRISPR Therapeutics AG CRSP	104 M	$ 55.17	2.47 %	$ 4.65 B	Schweiz
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	4.08 M	$ 29.43	6.09 %	$ 1.43 B	USA